IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. - Wikidata - awgldk - TriplyDB

IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis.

IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis.

http://www.wikidata.org/entity/Q27851565

about

Functions of TET Proteins in Hematopoietic Transformation New strategies in myelodysplastic syndromes: application of molecular diagnostics to clinical practice CIViC database IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients.IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations.Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate.Prognostic value of isocitrate dehydrogenase mutations in myelodysplastic syndromes: a retrospective cohort study and meta-analysis.The challenging world of cytopenias: distinguishing myelodysplastic syndromes from other disorders of marrow failure TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia.DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies Rare occurrence of DNMT3A mutations in myelodysplastic syndromes.IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients TET proteins and 5-methylcytosine oxidation in hematological cancers The Clinical Significance of IDH Mutations in Essential Thrombocythemia and Primary Myelofibrosis Is targeted therapy feasible in acute myelogenous leukemia?Molecular pathophysiology of myelodysplastic syndromes.IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer.Isocitrate dehydrogenase mutations in myeloid malignancies.Unraveling the molecular pathophysiology of myelodysplastic syndromes.5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia.Update on cytogenetic and molecular changes in myelodysplastic syndromes.Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2.Mutations in epigenetic regulators in myelodysplastic syndromes.The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes.The need for additional genetic markers for myelodysplastic syndrome stratification: what does the future hold for prognostication?Epigenetic alterations and microRNAs: new players in the pathogenesis of myelodysplastic syndromes.The emerging role of d-2-hydroxyglutarate as an oncometabolite in hematolymphoid and central nervous system neoplasms.Recent advances in understanding the molecular pathogenesis of myelodysplastic syndromes.Stem cell origin of myelodysplastic syndromes.Integrating genetics and epigenetics in myelodysplastic syndromes: advances in pathogenesis and disease evolution.I walk the line: how to tell MDS from other bone marrow failure conditions.The molecular pathogenesis of the myelodysplastic syndromes.Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.Secondary Adult Acute Myeloid Leukemia: a Review of Our Evolving Understanding of a Complex Disease Process.Diagnostic testing for IDH1 and IDH2 variants in acute myeloid leukemia an algorithmic approach using high-resolution melting curve analysis.Roles of IDH1/2 and TET2 mutations in myeloid disorders.

P2860

1c28c0577b6d2d71f53233835b93b4e083960c3f

P248

Q26778323-BEF472C7-72A6-4519-AEED-9A663585E1CB Q27016511-F895AAB8-DF92-4774-AF29-A50A8DDF7D5C Q27612411-A59D35A6-25A4-4A6D-96DB-1DCD034803C6 Q27851676-6323EF32-B3D4-4DC9-AFAC-E673C4FE0B40 Q27851680-C804A821-D012-45A5-A450-68CAB01B6F88 Q28066926-3A30E276-451F-49A3-BB61-7248FC50EBC2 Q33558105-AD009CDE-2AF3-41B9-A2AD-FD648402437F Q33699608-192AB335-56DE-400C-86DA-7F485DDDF5ED Q33769072-D0A1F293-415F-4958-B252-BFC89722EFE3 Q33829778-2AFE2FD4-DEDA-4E3B-97C2-1C897407CA44 Q34157339-4A325FE8-D463-4AFE-B81C-AF7442C7BB82 Q34661033-EB845832-D994-43B4-B648-05211B9866A9 Q35596955-22EE9F06-C791-43B4-8365-4387DC0D3A73 Q35835653-5A5C4534-C7F6-45CF-9B60-AE598EDD2D6F Q35873466-9E303C66-2689-44D8-941E-F1EF4216900B Q36197509-3CAFC18B-E8FF-4C0C-86AA-63BF9EF23001 Q36364763-14CCEF03-0BED-4550-81FC-5497F647BCCF Q36416358-E6E88CE7-78AA-4258-9B35-57846A600445 Q36445968-81E64B75-ED83-49F8-835B-2FA7C7824CFE Q36522731-9A8AEBF1-885D-4898-8F03-63C3F9C7BE54 Q36832167-3D3C5008-E5BA-420B-9C03-5ACE3A383A09 Q37625630-3567406A-A48E-42EF-AEAF-BBBF85F71EB3 Q37671806-4EC27E65-BB0C-4DD1-AE98-EE2B240D9219 Q37702702-C65F88CD-C5D1-4A0A-8FEE-ACBFCC1CEBC7 Q37923939-82220D22-DFD3-4B96-A27F-12A5A5F6B552 Q37955769-ABFC8E4D-D9CA-4FF3-91BF-9B492361F697 Q37974844-3DF38A0A-0629-418C-BBCF-E92A1DD75ABD Q38061848-0EDB8375-1117-4042-BC8E-8E0D7902D088 Q38078427-B53C8203-0623-4893-A922-4D3C75226026 Q38113961-278C019F-85C9-4931-870C-4DA0AA1F3A51 Q38121089-B849F246-4545-442A-A05A-2CB44C3C6235 Q38122703-CFE6E44D-CF25-4042-B61A-5DCBB0FF359C Q38171230-CBA5149B-D0A5-4617-8CB3-7C12AE7EDA49 Q38218055-4EE66FE8-4E73-41B4-AEF4-AC06A2FA031F Q38235622-EA8799A1-9290-4720-943F-D7095BAE21A7 Q38341998-5770C260-6AEA-4F5B-81A7-4A563FAF889A Q38420779-5FA19481-4A21-4CDA-B9E5-5336768629CE Q38542828-E37088FC-9B17-4976-8040-C61CBD217B6D Q38714577-2F72A06C-6C87-4F8C-B2A8-B876A56035C4 Q38775985-529361D4-B67B-413D-9F51-C49F486B412C

P2860

IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis.

http://www.wikidata.org/entity/Q27851565

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

IDH1 mutations in patients wit ...... with an unfavorable prognosis.

@ast

IDH1 mutations in patients wit ...... with an unfavorable prognosis.

@en

IDH1 mutations in patients wit ...... with an unfavorable prognosis.

@nl

type

label

IDH1 mutations in patients wit ...... with an unfavorable prognosis.

@ast

IDH1 mutations in patients wit ...... with an unfavorable prognosis.

@en

IDH1 mutations in patients wit ...... with an unfavorable prognosis.

@nl

altLabel

IDH1 mutations in patients wit ...... with an unfavorable prognosis

@en

prefLabel

IDH1 mutations in patients wit ...... with an unfavorable prognosis.

@ast

IDH1 mutations in patients wit ...... with an unfavorable prognosis.

@en

IDH1 mutations in patients wit ...... with an unfavorable prognosis.

@nl

P1433

Q27851565-67CE3D66-1D6C-4610-9CDD-0CF9565DE804

P1476

Q27851565-ED77E0AE-DFB0-4692-8CB3-F3DC8923D416

P2093

Q27851565-038B738F-FC07-4A59-9E9B-E4FEB1B7EE16

Q27851565-589C3B95-9569-43ED-AEDA-C1DF7090CE3B

Q27851565-7700BC12-EB7D-437E-8090-0AA554528008

Q27851565-7A38CE29-C658-492A-897D-F0BB7237DAB9

Q27851565-7B82FC10-6114-4FAB-8BF4-DF16CC93439A

Q27851565-8264AB86-2C06-4B91-B4D4-54EA547AE6CF

Q27851565-A1FBE527-93BA-493F-A8B6-6EAA94A41F1A

Q27851565-E7094EF8-A138-4727-B32E-412382D16C44

Q27851565-E786A07D-B9DC-4954-8267-38BCE065D9C3

Q27851565-E8255A53-E954-4E51-BB9A-5A7E4C9AD00B

P2860

Q27851565-118C1059-A3B3-4C86-AC25-65DBD1B86E30

Q27851565-19850609-24E2-4117-9DD3-FCE21DDC4785

Q27851565-1CB9FFEC-AF87-456E-91B9-3CEAAA1674A5

Q27851565-227B033E-865E-42A3-B567-CAD67DA1491F

Q27851565-327DAE8A-2A86-4229-9326-268D7FC50E2E

Q27851565-365A5381-CB47-4467-BF84-1947D290A37B

Q27851565-3E2C3C1A-2B51-4EA9-B4ED-0001EE6C0574

Q27851565-4FEFFE75-8DC8-47F3-9556-091055BE38F0

Q27851565-6D54A353-8945-48E5-B8F4-1CEFE88D27BE

Q27851565-70749AC7-9A5B-4B6A-B5A2-0BF5EE486B7F

P304

Q27851565-5C5CB273-9617-40E0-8D58-22EDA94CE0B3

P31

Q27851565-C23E30E5-D721-4996-9069-2BC9C6B2DA78

P3181

Q27851565-70C4A0EC-3381-4ACA-9EA9-4B3E18140F61

P356

Q27851565-C479E740-795E-4983-9DD4-2FD05CB3C271

P433

Q27851565-24330F8B-B0C7-4729-9FCE-697ACD82CD94

P478

Q27851565-FCAAF189-E577-4E15-9483-CDD742D8710D

P50

Q27851565-0CDA2CF5-7EA8-40C3-98B8-E1ED97C6C5D9

Q27851565-826A3448-FAA7-47A9-B47F-1F595CB04192

P577

Q27851565-FF12E6C5-2CE8-4CC9-8577-132927E44F22

P5875

Q27851565-C806724D-342C-4219-B875-8FD22C238E17

P698

Q27851565-2049BB3B-0D2C-43B1-BC27-2C5301F4D26F

P921

Q27851565-9C7652EC-97D5-4B8F-A74B-84361AC6F152

P932

Q27851565-4B1D8657-9575-4507-9FBE-4C6978031867

P3181

P356

HAEMATOL.2010.025494

P1433

P1476

IDH1 mutations in patients wit ...... with an unfavorable prognosis.

@en

P2093

Arnold Ganser

http://www.w3.org/2001/XMLSchema#string

Christiane Schumann

http://www.w3.org/2001/XMLSchema#string

Eva M Weissinger

http://www.w3.org/2001/XMLSchema#string

Felicitas Thol

http://www.w3.org/2001/XMLSchema#string

Frederik Damm

http://www.w3.org/2001/XMLSchema#string

Gesine Bug

http://www.w3.org/2001/XMLSchema#string

Gudrun Göhring

http://www.w3.org/2001/XMLSchema#string

Jürgen Krauter

http://www.w3.org/2001/XMLSchema#string

Katharina Wagner

http://www.w3.org/2001/XMLSchema#string

Martin Wichmann

http://www.w3.org/2001/XMLSchema#string

P2860

FMS mutations in myelodysplastic, leukemic, and normal subjects

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

Recurring mutations found by sequencing an acute myeloid leukemia genome

An integrated genomic analysis of human glioblastoma multiforme

IDH1 and IDH2 mutations in gliomas

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.

Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.

International scoring system for evaluating prognosis in myelodysplastic syndromes

P304

1668-74

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3690022

http://www.w3.org/2001/XMLSchema#string

P356

10.3324/HAEMATOL.2010.025494

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

95

http://www.w3.org/2001/XMLSchema#string

P50

Brigitte Schlegelberger

P577

2010-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44623077

http://www.w3.org/2001/XMLSchema#string

P698

20494930

http://www.w3.org/2001/XMLSchema#string

P921

P932

2948091

http://www.w3.org/2001/XMLSchema#string